Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

S095024

Monoclonal antibody · Inhibitor of 5'-ecto-nucleotidase (CD73) (NT5E)

Phase 1/2 Most advanced trial
1 Registered trials

What is S095024?

S095024 is a monoclonal antibody that binds CD73 (NT5E), an ectoenzyme that converts extracellular AMP to adenosine, and inhibits its activity. By reducing adenosine-mediated immunosuppression, it is intended to enhance cytotoxic T-lymphocyte activity. It is studied in non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
5'-ecto-nucleotidase (CD73) (NT5E)
Mechanism
Inhibitor of 5'-ecto-nucleotidase (CD73) (NT5E)
Pathways
adenosine-mediated immunosuppression, CD73-mediated conversion of AMP to adenosine
Therapy area
Oncology
In trials of
REGN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06162572 Phase 1/2 Non-small Cell Lung Cancer (NSCLC) Active not recruiting REGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non-small Cell Lung Cancer (NSCLC)

Other drugs acting on NT5E

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.